Recursion Pharmaceuticals, Inc. RXRX Accrued Progress Collections and Price Adjustments
Accrued Progress Collections and Price Adjustments at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s accrued progress collections and price adjustments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s accrued progress collections and price adjustments?
- Recursion Pharmaceuticals, Inc. (RXRX) reported accrued progress collections and price adjustments of $114.72M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s accrued progress collections and price adjustments changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s accrued progress collections and price adjustments decreased by 11.5% year-over-year, from $129.61M to $114.72M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s accrued progress collections and price adjustments?
- Over 5 years (2020 to 2025), Recursion Pharmaceuticals, Inc.'s accrued progress collections and price adjustments has grown at a 46.9% compound annual growth rate (CAGR), from $16.67M to $114.01M.